Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Adagrasib (MRTX849) is a KRAS(G12C) inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with KRAS(G12C)-mutated solid tumors, including patients with CNS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun, Johnson, Melissa, Barve, Minal, Bazhenova, Lyudmila, McCarthy, Marybeth, Schwartz, Rowena, Horvath-Walsh, Elise, Velastegui, Karen, Qian, Chunlin, Spira, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078892/
https://www.ncbi.nlm.nih.gov/pubmed/36892150
http://dx.doi.org/10.1093/oncolo/oyad051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078892/
https://www.ncbi.nlm.nih.gov/pubmed/36892150
http://dx.doi.org/10.1093/oncolo/oyad051

Ejemplares similares